Last reviewed · How we verify
Squamous cell carcinoma of larynx
Approved treatments
- Erbitux · Imclone
Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division. - Erbitux · Hellenic Oncology Research Group
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Squamous cell carcinoma of larynx patent landscape — cliff calendar, originator estates, attackable patents
- Squamous cell carcinoma of larynx treatment landscape brief
- Squamous cell carcinoma of larynx treatment updates RSS
Frequently asked questions about Squamous cell carcinoma of larynx
What drugs treat Squamous cell carcinoma of larynx?
Tracked treatments include Erbitux.
What is the treatment for Squamous cell carcinoma of larynx?
Standard treatment for Squamous cell carcinoma of larynx includes Erbitux. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Squamous cell carcinoma of larynx patent cliff · Squamous cell carcinoma of larynx CI report
- Treatment: Erbitux · Imclone
- Treatment: Erbitux · Hellenic Oncology Research Group
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing